Exclusion Criteria:~1. Received an investigational product in another clinical study during the last 4 weeks
prior to screening~2. Diagnosis of Type 1 diabetes~3. Diagnosis of Type 2 diabetes treated with insulin,
sulfonylureas, glucagon like peptide1 receptor agonists (GLP-1), thiazolidinedione (TZD) or SGLT2 inhibitors
(metformin monotherapy is allowed).~4. Estimated Glomerular Filtration Rate (eGFR; MDRD) <45 mL/min at
screening or unstable renal disease.~5. Any condition when MRI is contraindicated such as, but not limited to,
having a pacemaker or claustrophobia.~6. Severe hepatic injury and/or significant abnormal liver function
defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase
(ALT) >3x ULN. Total bilirubin >2.0 mg/dL (34.2 Î¼mol/L)~7. Intolerance or allergy to dapaglifozin or any other
SGLT2 inhibitor or any other substance in the tablets.~8. Dementia due to causes other than AD~9. History of
recurrent urinary tract infection~10. Active mycotic genital infection~11. History of bladder cancer~12.
History of diabetic ketoacidosis~13. Potentially confounding, serious, or unstable medical conditions such as:~
1. cancer within the past 3 years (except basal cell, squamous cell, or localized prostate cancer)~ 2. a recent
cardiac event (i.e. heart attack, angioplasty, etc. within the 3 months prior to screening visit)~ 3. other
conditions that pose a potential safety risk or confounding factor in the investigator's opinion~14. Any
abnormal physical examination assessment or vital sign assessment at the screening visit that is deemed to be
clinically significant by the principal investigator.~15. Any abnormal clinical laboratory test result at the
screening visit that is deemed to be clinically significant by the principal investigator.
